{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:56:41Z","timestamp":1778291801584,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.beha.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T06:42:03Z","timestamp":1309243323000},"page":"369-379","source":"Crossref","is-referenced-by-count":47,"title":["Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need"],"prefix":"10.1016","volume":"24","author":[{"given":"Avichai","family":"Shimoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2011.05.002_bib1","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2011.05.002_bib2","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2011.05.002_bib3","author":"Center for International Blood and Marrow Transplantation"},{"key":"10.1016\/j.beha.2011.05.002_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2000.02196.x","article-title":"Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.05.002_bib5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib6","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib7","first-page":"21","article-title":"Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission","volume":"3","author":"Helenglass","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors","volume":"14","author":"Anderson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2011.05.002_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","article-title":"Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2010.06.017","article-title":"Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination","volume":"17","author":"Almog","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"Kashyap","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d\u2019Etudes de la Greffe de Moelle Osseuse","volume":"79","author":"Blaise","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib15","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.2002.03973.x","article-title":"Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission","volume":"119","author":"Litzow","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2011.05.002_bib16","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","article-title":"Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies","volume":"98","author":"Soci\u00e9","year":"2001","journal-title":"Blood"},{"issue":"Suppl2","key":"10.1016\/j.beha.2011.05.002_bib17","article-title":"Comparison of outcomes after allogeneic SCT for adult patients with AML in remission using either I.V. busulfan plus cyclophosphamide or TBI plus cy in the myeloablative conditioning regimen: an- ALWP-EBMT survey [abstract]","volume":"45","author":"Nagler","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib18","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib19","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib22","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.05.002_bib24","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.leu.2403591","article-title":"Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning","volume":"19","author":"Shimoni","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.05.002_bib26","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.05.002_bib27","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood-2005-11-4503","article-title":"Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib28","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.10867","article-title":"Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia","volume":"92","author":"Blaise","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2011.05.002_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1705965","article-title":"High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission","volume":"41","author":"Schmid","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbmt.2003.10.006","article-title":"Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation","volume":"10","author":"Couriel","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","article-title":"Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival","volume":"26","author":"Valc\u00e1rcel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/leu.2008.164","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a \u2018donor\u2019 versus \u2018no donor\u2019 comparison","volume":"23","author":"Mohty","year":"2009","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2011.05.002_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1182\/blood.V114.22.274.274","volume":"114","author":"Farag","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"Suppl2","key":"10.1016\/j.beha.2011.05.002_bib37","article-title":"Comparison of low-dose TBI-based reduced-intensity conditioning (RIC) vs. chemotherapy-based RIC prior to allogeneic stem cell transplantation (allo-SCT) from an HLA identical sibling donor for AML in first complete remission [abstract]","volume":"45","author":"Mohty","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/sj.leu.2404886","volume":"21","author":"Shimoni","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2011.05.002_bib39","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.2006.09.7865","article-title":"Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation","volume":"25","author":"Sorror","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.05.002_bib40","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/leu.2010.12","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up","volume":"24","author":"Shimoni","year":"2010","journal-title":"Leukemia"},{"issue":"Suppl2","key":"10.1016\/j.beha.2011.05.002_bib41","first-page":"s55","article-title":"Comparison of Bu-Cy-based standard myeloablative conditioning vs. fludarabine and busulfan (Flu-Bu)-based reduced-intensity conditioning [abstract]","volume":"45","author":"Mohty","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib45","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","article-title":"Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide","volume":"14","author":"Bredeson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib48","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428190701671051","article-title":"Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"48","author":"Shimoni","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2011.05.002_bib49","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","article-title":"Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning","volume":"28","author":"Casper","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2011.05.002_bib50","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V116.21.3473.3473","article-title":"Fludarabine and treosulfan conditioning for allogeneic stem-cell transplantation; a dose- intense regimen with limited toxicity [abstract]","volume":"116","author":"Shimoni","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib51","doi-asserted-by":"crossref","unstructured":"Shimoni A, Rand A, Shem-Tov N, et\u00a0al. Reduced toxicity myeloablative conditioning regimens (RTC) compared with standard myeloablative conditioning prior to allogeneic stem cell transplantation in AML and MDS; RTC has more favorable toxicity profile but more limited leukemia control in advanced disease [Abstract]. Bone Marrow Transplant 2011;46(Suppl 1):s46--7. Abstract 289.","DOI":"10.1016\/j.bbmt.2010.12.277"},{"key":"10.1016\/j.beha.2011.05.002_bib52","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3109\/10428194.2010.520773","article-title":"Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"51","author":"O\u2019Donnell","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2011.05.002_bib53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","article-title":"High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen","volume":"14","author":"Geddes","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","article-title":"The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia","volume":"16","author":"Russell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2011.05.002_bib55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajh.21630","article-title":"Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients","volume":"85","author":"Takahata","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2011.05.002_bib56","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.05.002_bib57","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. Busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","author":"Andersson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.beha.2011.05.002_bib58","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2005.05.694","article-title":"Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older","volume":"20","author":"Wallen","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T22:22:15Z","timestamp":1592691735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1521692611000478"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.05.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}